Two cases being argued in July at the Federal Circuit attracted amicus briefs. One of those cases is Sun Pharmaceutical Industries, Inc. v. Incyte Corporation. In this case, the Federal Circuit will review a decision by the Patent Trial and Appeal Board that the inter partes review petitioner “has shown by a preponderance of the evidence that the challenged claims are unpatentable.” Notably, in this case, Sun Pharmaceutical Industries was substituted for Concert Pharmaceuticals as the appellant to reflect a recent merger. This is our argument preview.
- 1
- 2